Search
Simulations Plus Inc
SLPAdd to Watchlist
18.390USD
+0.040+0.22%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
371.58MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.22%
5 Days
+1.04%
1 Month
+10.45%
6 Months
+1.55%
Year to Date
+0.88%
1 Year
+3.61%
Key Figures
18.450Open
18.470High
483.05KVolume
LossP/E TTM
38.27P/E Dynamic
--Dividend TTM
2.39%Turnover Ratio
18.350Prev. Close
18.340Low
5.03MTurnover
LossP/E Static
2.78P/B
0.00%Div Yield TTM
-36.09%ROA
32.51552wk High
1.15Volume Ratio
-64.72MNet Profit
20.21MShares
-3.1244EPS TTM
1.31Beta
-38.84%ROE
11.09052wk Low
0.71%Amplitude
66.46%Gross Margin
371.58MMarket Cap
3.04Reward/Risk
3.36%Risk Rate
TradingKey Stock Score of Simulations Plus Inc
Currency: USD Updated: 2026-07-02Key Insights
Simulations Plus Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 19.83.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Simulations Plus Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Simulations Plus Inc Highlights
StrengthsRisks
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.90% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.18M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -5.89, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 17.68M shares, decreasing 20.75% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 324.76K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.59.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
19.833
Target Price
+8.08%
Upside Space
Simulations Plus Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Simulations Plus Inc Info
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
Ticker SymbolSLP
CompanySimulations Plus Inc
CEOO'Connor (Shawn M)
Websitehttps://www.simulations-plus.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Simulations Plus Inc (SLP)?
The current price of Simulations Plus Inc (SLP) is 18.39.
What is the symbol of Simulations Plus Inc?
The ticker symbol of Simulations Plus Inc is SLP.
What is the 52-week high of Simulations Plus Inc?
The 52-week high of Simulations Plus Inc is 32.52.
What is the 52-week low of Simulations Plus Inc?
The 52-week low of Simulations Plus Inc is 11.09.
What is the market capitalization of Simulations Plus Inc?
The market capitalization of Simulations Plus Inc is 371.58M.
Is Simulations Plus Inc (SLP) currently rated as Buy, Hold, or Sell?
According to analysts, Simulations Plus Inc (SLP) has an overall rating of signal_hold, with a price target of 19.83.
What is the Earnings Per Share (EPS TTM) of Simulations Plus Inc (SLP)?
The Earnings Per Share (EPS TTM) of Simulations Plus Inc (SLP) is -3.22.